Who We Are
Delivering on our promise for patients
Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
We are led by an experienced international management team. Our proprietary product pipeline and next-generation antibody technologies are the result of our strong company culture and a deep passion for innovation. We are inspired by nature and the power of the immune system to transform cancer treatment.
OUR PURPOSE
Combating cancer through the power of human antibodies
Our core purpose is to improve the lives of patients with cancer by creating and developing innovative and differentiated antibody products. It is our reason for being.
Our core values
In our quest to turn science into medicine, we use these guideposts to transform the future of cancer treatment:
- Passion for innovation
- Determination—being the best at what we do
- Integrity—we do the right thing
- We work as one team and respect each other
Our key accomplishments
Each of our achievements stands as evidence of our unyielding determination, including:
- Creators of three marketed products*
- Inventors of four proprietary technologies
- Growing multiple proprietary clinical programs
- Pioneers of a robust pre-clinical pipeline
- World-class leaders with antibody and R&D expertise
- Partners of choice with strategic collaborations
- Solid financials
- Building and expanding our capabilities with approximately 600 employees across our four international locations
Use our Investor’s Fact Sheet to get a snapshot of our achievements, our process and our financials.
Out-licensed products marketed by partner
Join our mission
Be a part of our team and help transform the future of cancer treatment
Turning insights into medicine
See the results of innovation that is rooted in science
Putting our expertise to work
See how we put our in-depth knowledge of antibody biology into action